Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute

[1] AAPRO MS, 1995, SEMIN ONCOL, V22, P1

[2] ABELOFF MD, 1995, SEMIN ONCOL, V22, P1

[3] [Anonymous], 1992, Lancet

[4] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) : 1539 - 1545

[5] BONADONNA G, 1992, CANCER RES, V52, P2127

[6] Bonadonna G, 1995, Surg Oncol Clin N Am, V4, P701

[7] CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) : 901 - 906

[8] PRIMARY CHEMOTHERAPY IN SURGICALLY RESECTABLE BREAST-CANCER [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1995, 45 (04) : 227 - 243

[9] BONADONNA G, IN PRESS SEMIN ONCOL

[10] Bonadonna Gianni, 1995, JAMA (Journal of the American Medical Association), V273, P542, DOI 10.1001/jama.273.7.542

[1] AAPRO MS, 1995, SEMIN ONCOL, V22, P1

[2] ABELOFF MD, 1995, SEMIN ONCOL, V22, P1

[3] [Anonymous], 1992, Lancet

[4] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) : 1539 - 1545

[5] BONADONNA G, 1992, CANCER RES, V52, P2127

[6] Bonadonna G, 1995, Surg Oncol Clin N Am, V4, P701

[7] CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) : 901 - 906

[8] PRIMARY CHEMOTHERAPY IN SURGICALLY RESECTABLE BREAST-CANCER [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1995, 45 (04) : 227 - 243

[9] BONADONNA G, IN PRESS SEMIN ONCOL

[10] Bonadonna Gianni, 1995, JAMA (Journal of the American Medical Association), V273, P542, DOI 10.1001/jama.273.7.542